On October 22, 2020 Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, reported that members of the Company’s immuno-oncology team will provide an overview of the company’s early-stage immuno-oncology research, specifically the AL008 development program, at two upcoming virtual scientific meetings (Press release, Alector, OCT 22, 2020, View Source [SID1234568825]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
AL008 is a novel, investigational, antibody product candidate targeting the CD47-SIRP-alpha (SIRPα) pathway, a potent survival pathway co-opted by tumors to evade the innate immune system. AL008 is a potential best-in-class SIRPα inhibitor with a unique dual mechanism of action that non‑competitively antagonizes the CD47- SIRPα pathway by inducing the internalization and degradation of the inhibitory receptor on macrophages to relieve immune suppression (a "don’t eat me signal") while also engaging and activating Fcγ gamma receptor (FcγgammaR) to promote immuno-stimulatory pathways that drive anti-tumor immunity.
The virtual scientific meetings include the:
Macrophage-Directed Therapies Summit
Date and Time: Wednesday, October 28, 2020 at 10:30 a.m. EST
Presentation: A Novel Approach to Targeting the SIRPα Checkpoint Pathway and FcγgammaR Signaling
Presenter: Spencer Liang, Ph.D., senior director and head of immuno-oncology
CD47|SIRPα Summit
Date and Time: Wednesday, November 4, 2020 at 4:30 p.m. EST
Panel: What are the Predictive Biomarkers Arising When Targeting CD47|SIRPα Pathways?
Presenter: Spencer Liang, Ph.D., senior director and head of immuno-oncology
Date and Time: Thursday, November 5, 2020 at 11:35 a.m. EST
Presentation: An Insight into Alector’s Novel Approach to Drive Anti-Tumor Immunity Targeting CD47|SIRPα Pathways
Presenter: Andrew Picentic, Ph.D., senior staff scientist and group leader
Date and Time: Thursday, November 5, 2020 at 11:35 a.m. EST
Panel: How Can We Manage Toxicity and Improve Clinical Practice in Targeting CD47|SIRPα Pathways?
Presenter: Daniel Maslyar, M.D., vice president of clinical development, oncology
"We are pleased to be highlighting the progress of our early-stage immuno-oncology programs at two notable research forums," said Arnon Rosenthal, Ph.D., co-founder and chief executive officer of Alector. "Despite the tremendous progress that has been made in the treatment landscape for cancer in the last 20 years, the need for additional, effective treatment options remains. Alector is leveraging its knowledge of the innate immune system, with the goal of developing novel, first-in-class therapies for patients who need new treatments."